Multiple Chinese Firms Expand Global Phase III Trials To Japan
Rule Change Eases Moves
The efforts add up to a new trend after Chinese pharma firms embarked on a quest to launch pivotal Phase II or III trials worldwide, especially in the US and Europe, over the past decade. Meanwhile, BeiGene, Hengrui and others are advancing late-stage programs in the US.
